14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VOR vs WVE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 7–2 Matrix Metrics)
VOR Overall Winner
6-Pillar Tally: VOR 2 – 2 WVE (2 Tie)
Matrix Metrics: VOR 7 – 2 WVE
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Wave Life Sciences Ltd. (WVE) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin), whereas WVE carries 41.5/100 (SELL) at $2.87 (N/M Forward P/E, -320.9% operating margin).
Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. WVE 41.5/100 SELL) and 1.90β · 61% Vol risk profile, whereas WVE leads top-line expansion (+73.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile WVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs WVE. Trailing 12-month operating profitability (VOR 0.0% vs WVE -320.9%) and valuation multiples (VOR N/M vs WVE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $617.3M market capitalization and -320.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VOR vs WVE Key Questions & Quantitative Answers
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Wave Life Sciences Ltd. (WVE) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin), whereas WVE carries 41.5/100 (SELL) at $2.87 (N/M Forward P/E, -320.9% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. WVE 41.5/100 SELL) and 1.90β · 61% Vol risk profile, whereas WVE leads top-line expansion (+73.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile WVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
WVE leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with WVE at +73.0% YoY revenue growth and +0.0% YoY earnings growth on $71M TTM revenue (N/A gross margin, -320.9% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $71M for WVE. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for WVE.
VOR and WVE trade at balanced relative valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas WVE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus WVE (-78.8% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 120.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk). By comparison, WVE carries 463.8% implied volatility (48th %ile, Balanced (25th–60th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.94β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.